An FDA Green Light Could Be in this Underfollowed Biotech Company's Future!

This first-in-class biotechnology company with the world's ONLY fully human anti-CD3 monoclonal antibody in clinical development should be... ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ Unsubscribe

A Message from Smallcaps Daily This first-in-class biotechnology company with the world’s ONLY fully human anti-CD3 monoclonal antibody in clinical development should be high on your radar! There is currently still no cure for neurodegenerative diseases such as Alzheimer's, MS, and ALS. The rise in diagnoses can be attributed to the aging population as life expectancy increases. Not only is this a growing health concern, but the annual cost to the US from Alzheimer’s disease and related dementias and other neurodegenerative diseases is tremendous. It was $655 billion in 2020! Now more than ever we need treatments to fight these terrible diseases. One underfollowed NASDAQ company in the biotech space is uniquely standing out as it focuses on developing drugs with a unique approach for these rising diseases. This clinical-stage biotechnology company specializes in developing transformative therapies for neurodegenerative and lung diseases. The Company’s clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS, Alzheimer's, Crohn's Disease and KRAS NSCLC. The company’s “wonder drug” is the world’s only fully human anti-CD3 monoclonal antibody in clinical development! Activated T cells play an important role in the inflammatory process. The company’s drug binds to the T cell receptor and dampens inflammation by modulating T cell function, thereby suppressing effector features in multiple immune cell subsets. This effect has been demonstrated in patients with COVID and with multiple sclerosis, as well as in healthy normal subjects. With its revolutionary approach to attacking neurodegenerative and lung diseases, this company has the potential to change the way immunotherapies are currently conducted and may be a promising gem hiding in the biotech arena. Learn More to See How This Undiscovered Biotech Has Blockbuster Potential With The Only Fully Human Anti-CD3 Monoclonal Antibody In Clinical Development!

Thank you for subscribing to Insider Trades Daily, which covers the most recent insider buying and selling activity from Wall Street CEO's, CFO's, COO's and other insiders.   This message is a paid advertisement sent on behalf of Smallcaps Daily, a third-party advertiser of InsiderTrades.com and MarketBeat.     This message is a paid advertisement for Tiziana Life Sciences (NASDAQ: TLSA) from Smallcaps Daily and Interactive Offers. MarketBeat Media, LLC receives a fixed fee for each subscriber that clicks on a link in this email, totaling up to $1,500. Other than the compensation received for this advertisement sent to subscribers, MarketBeat and its principals are not affiliated with either Smallcaps Daily or Interactive Offers. MarketBeat and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither MarketBeat nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from MarketBeat to buy or sell any security. MarketBeat has not evaluated the accuracy of any claims made in this advertisement. MarketBeat recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding Tiziana Life Sciences (NASDAQ: TLSA) on Interactive Offers' website for additional information about the relationship between Interactive Offers and Tiziana Life Sciences (NASDAQ: TLSA).     If you have questions about your subscription, feel free to contact our U.S. based support team via email at contact@marketbeat.com.   If you no longer wish to receive email from InsiderTrades.com, you can unsubscribe.   © 2006-2024 MarketBeat Media, LLC. 345 N Reid Place, Suite 620, Sioux Falls, SD 57103. United States.   Today's Bonus Content: Biden to drop out; finish out his term?